English
简体中文
Total: £ 56.28
Published Date: 2025-11-05 | Pages: 142 | Tables: 142 | Medical Care
The global Drug Treatment for Respiratory Disease market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Respiratory diseases may be caused by infection, by smoking tobacco, or by breathing in secondhand tobacco smoke, radon, asbestos, or other forms of air pollution. Respiratory diseases include asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, and lung cancer.
Nebulization inhalation therapy is an important treatment method for respiratory system-related diseases. Compared with oral administration, intramuscular injection and intravenous administration, aerosol inhalation therapy has the advantages of rapid onset of action, good curative effect, fewer systemic adverse reactions, and does not require the patient's deliberate cooperation because the drug directly acts on the target organ. It has been adopted domestically. Widely used outside.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Drug Treatment for Respiratory Disease market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Novartis
Mylan
Vertex Pharmaceuticals
F. Hoffman La Roche
Teva Pharmaceuticals
Cipla
Fibrogen
Liminal Biosciences
PharmAkea Therapeutics
IQVIA
Segment by Type
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Diseases
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Drug Treatment for Respiratory Disease study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Drug Treatment for Respiratory Disease: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Drug Treatment for Respiratory Disease Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Asthma
1.2.3 Chronic Obstructive Pulmonary Disease (COPD)
1.2.4 Lung Cancer
1.2.5 Other Diseases
1.3 Market Segmentation by Application
1.3.1 Global Drug Treatment for Respiratory Disease Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Drug Treatment for Respiratory Disease Revenue Estimates and Forecasts 2020-2031
2.2 Global Drug Treatment for Respiratory Disease Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Drug Treatment for Respiratory Disease Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Drug Treatment for Respiratory Disease Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Asthma Market Size by Players
3.3.2 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Players
3.3.3 Lung Cancer Market Size by Players
3.3.4 Other Diseases Market Size by Players
3.4 Global Drug Treatment for Respiratory Disease Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Drug Treatment for Respiratory Disease Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Drug Treatment for Respiratory Disease Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Drug Treatment for Respiratory Disease Market Size by Type (2020-2031)
6.4 North America Drug Treatment for Respiratory Disease Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Drug Treatment for Respiratory Disease Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Drug Treatment for Respiratory Disease Market Size by Type (2020-2031)
7.4 Europe Drug Treatment for Respiratory Disease Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Drug Treatment for Respiratory Disease Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Drug Treatment for Respiratory Disease Market Size by Type (2020-2031)
8.4 Asia-Pacific Drug Treatment for Respiratory Disease Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Drug Treatment for Respiratory Disease Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Drug Treatment for Respiratory Disease Market Size by Type (2020-2031)
9.4 Central and South America Drug Treatment for Respiratory Disease Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Drug Treatment for Respiratory Disease Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Drug Treatment for Respiratory Disease Market Size by Type (2020-2031)
10.4 Middle East and Africa Drug Treatment for Respiratory Disease Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Drug Treatment for Respiratory Disease Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Drug Treatment for Respiratory Disease Product Features and Attributes
11.1.4 GSK Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.1.5 GSK Drug Treatment for Respiratory Disease Revenue by Product in 2024
11.1.6 GSK Drug Treatment for Respiratory Disease Revenue by Application in 2024
11.1.7 GSK Drug Treatment for Respiratory Disease Revenue by Geographic Area in 2024
11.1.8 GSK Drug Treatment for Respiratory Disease SWOT Analysis
11.1.9 GSK Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Drug Treatment for Respiratory Disease Product Features and Attributes
11.2.4 AstraZeneca Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.2.5 AstraZeneca Drug Treatment for Respiratory Disease Revenue by Product in 2024
11.2.6 AstraZeneca Drug Treatment for Respiratory Disease Revenue by Application in 2024
11.2.7 AstraZeneca Drug Treatment for Respiratory Disease Revenue by Geographic Area in 2024
11.2.8 AstraZeneca Drug Treatment for Respiratory Disease SWOT Analysis
11.2.9 AstraZeneca Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Drug Treatment for Respiratory Disease Product Features and Attributes
11.3.4 Boehringer Ingelheim Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.3.5 Boehringer Ingelheim Drug Treatment for Respiratory Disease Revenue by Product in 2024
11.3.6 Boehringer Ingelheim Drug Treatment for Respiratory Disease Revenue by Application in 2024
11.3.7 Boehringer Ingelheim Drug Treatment for Respiratory Disease Revenue by Geographic Area in 2024
11.3.8 Boehringer Ingelheim Drug Treatment for Respiratory Disease SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Drug Treatment for Respiratory Disease Product Features and Attributes
11.4.4 Novartis Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Drug Treatment for Respiratory Disease Revenue by Product in 2024
11.4.6 Novartis Drug Treatment for Respiratory Disease Revenue by Application in 2024
11.4.7 Novartis Drug Treatment for Respiratory Disease Revenue by Geographic Area in 2024
11.4.8 Novartis Drug Treatment for Respiratory Disease SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Mylan
11.5.1 Mylan Corporation Information
11.5.2 Mylan Business Overview
11.5.3 Mylan Drug Treatment for Respiratory Disease Product Features and Attributes
11.5.4 Mylan Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.5.5 Mylan Drug Treatment for Respiratory Disease Revenue by Product in 2024
11.5.6 Mylan Drug Treatment for Respiratory Disease Revenue by Application in 2024
11.5.7 Mylan Drug Treatment for Respiratory Disease Revenue by Geographic Area in 2024
11.5.8 Mylan Drug Treatment for Respiratory Disease SWOT Analysis
11.5.9 Mylan Recent Developments
11.6 Vertex Pharmaceuticals
11.6.1 Vertex Pharmaceuticals Corporation Information
11.6.2 Vertex Pharmaceuticals Business Overview
11.6.3 Vertex Pharmaceuticals Drug Treatment for Respiratory Disease Product Features and Attributes
11.6.4 Vertex Pharmaceuticals Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.6.5 Vertex Pharmaceuticals Recent Developments
11.7 F. Hoffman La Roche
11.7.1 F. Hoffman La Roche Corporation Information
11.7.2 F. Hoffman La Roche Business Overview
11.7.3 F. Hoffman La Roche Drug Treatment for Respiratory Disease Product Features and Attributes
11.7.4 F. Hoffman La Roche Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.7.5 F. Hoffman La Roche Recent Developments
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Corporation Information
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Drug Treatment for Respiratory Disease Product Features and Attributes
11.8.4 Teva Pharmaceuticals Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.8.5 Teva Pharmaceuticals Recent Developments
11.9 Cipla
11.9.1 Cipla Corporation Information
11.9.2 Cipla Business Overview
11.9.3 Cipla Drug Treatment for Respiratory Disease Product Features and Attributes
11.9.4 Cipla Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.9.5 Cipla Recent Developments
11.10 Fibrogen
11.10.1 Fibrogen Corporation Information
11.10.2 Fibrogen Business Overview
11.10.3 Fibrogen Drug Treatment for Respiratory Disease Product Features and Attributes
11.10.4 Fibrogen Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Liminal Biosciences
11.11.1 Liminal Biosciences Corporation Information
11.11.2 Liminal Biosciences Business Overview
11.11.3 Liminal Biosciences Drug Treatment for Respiratory Disease Product Features and Attributes
11.11.4 Liminal Biosciences Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.11.5 Liminal Biosciences Recent Developments
11.12 PharmAkea Therapeutics
11.12.1 PharmAkea Therapeutics Corporation Information
11.12.2 PharmAkea Therapeutics Business Overview
11.12.3 PharmAkea Therapeutics Drug Treatment for Respiratory Disease Product Features and Attributes
11.12.4 PharmAkea Therapeutics Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.12.5 PharmAkea Therapeutics Recent Developments
11.13 IQVIA
11.13.1 IQVIA Corporation Information
11.13.2 IQVIA Business Overview
11.13.3 IQVIA Drug Treatment for Respiratory Disease Product Features and Attributes
11.13.4 IQVIA Drug Treatment for Respiratory Disease Revenue and Gross Margin (2020-2025)
11.13.5 IQVIA Recent Developments
12 Drug Treatment for Respiratory DiseaseIndustry Chain Analysis
12.1 Drug Treatment for Respiratory Disease Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Drug Treatment for Respiratory Disease Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Drug Treatment for Respiratory Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Drug Treatment for Respiratory Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Drug Treatment for Respiratory Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Drug Treatment for Respiratory Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Drug Treatment for Respiratory Disease Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Drug Treatment for Respiratory Disease Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Drug Treatment for Respiratory Disease Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Drug Treatment for Respiratory Disease Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Drug Treatment for Respiratory Disease by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug Treatment for Respiratory Disease as of 2024)
Table 11. Global Drug Treatment for Respiratory Disease Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Drug Treatment for Respiratory Disease Companies Headquarters
Table 13. Global Drug Treatment for Respiratory Disease Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Drug Treatment for Respiratory Disease Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Drug Treatment for Respiratory Disease Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Drug Treatment for Respiratory Disease Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Drug Treatment for Respiratory Disease Revenue by Application (2026-2031) & (US$ Million)
Table 21. Drug Treatment for Respiratory Disease High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Drug Treatment for Respiratory Disease Growth Accelerators and Market Barriers
Table 25. North America Drug Treatment for Respiratory Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Drug Treatment for Respiratory Disease Growth Accelerators and Market Barriers
Table 27. Europe Drug Treatment for Respiratory Disease Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Drug Treatment for Respiratory Disease Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Drug Treatment for Respiratory Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Drug Treatment for Respiratory Disease Investment Opportunities and Key Challenges
Table 31. Central and South America Drug Treatment for Respiratory Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Drug Treatment for Respiratory Disease Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Drug Treatment for Respiratory Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. GSK Corporation Information
Table 35. GSK Description and Major Businesses
Table 36. GSK Product Features and Attributes
Table 37. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. GSK Revenue Proportion by Product in 2024
Table 39. GSK Revenue Proportion by Application in 2024
Table 40. GSK Revenue Proportion by Geographic Area in 2024
Table 41. GSK Drug Treatment for Respiratory Disease SWOT Analysis
Table 42. GSK Recent Developments
Table 43. AstraZeneca Corporation Information
Table 44. AstraZeneca Description and Major Businesses
Table 45. AstraZeneca Product Features and Attributes
Table 46. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. AstraZeneca Revenue Proportion by Product in 2024
Table 48. AstraZeneca Revenue Proportion by Application in 2024
Table 49. AstraZeneca Revenue Proportion by Geographic Area in 2024
Table 50. AstraZeneca Drug Treatment for Respiratory Disease SWOT Analysis
Table 51. AstraZeneca Recent Developments
Table 52. Boehringer Ingelheim Corporation Information
Table 53. Boehringer Ingelheim Description and Major Businesses
Table 54. Boehringer Ingelheim Product Features and Attributes
Table 55. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Boehringer Ingelheim Revenue Proportion by Product in 2024
Table 57. Boehringer Ingelheim Revenue Proportion by Application in 2024
Table 58. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2024
Table 59. Boehringer Ingelheim Drug Treatment for Respiratory Disease SWOT Analysis
Table 60. Boehringer Ingelheim Recent Developments
Table 61. Novartis Corporation Information
Table 62. Novartis Description and Major Businesses
Table 63. Novartis Product Features and Attributes
Table 64. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Novartis Revenue Proportion by Product in 2024
Table 66. Novartis Revenue Proportion by Application in 2024
Table 67. Novartis Revenue Proportion by Geographic Area in 2024
Table 68. Novartis Drug Treatment for Respiratory Disease SWOT Analysis
Table 69. Novartis Recent Developments
Table 70. Mylan Corporation Information
Table 71. Mylan Description and Major Businesses
Table 72. Mylan Product Features and Attributes
Table 73. Mylan Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Mylan Revenue Proportion by Product in 2024
Table 75. Mylan Revenue Proportion by Application in 2024
Table 76. Mylan Revenue Proportion by Geographic Area in 2024
Table 77. Mylan Drug Treatment for Respiratory Disease SWOT Analysis
Table 78. Mylan Recent Developments
Table 79. Vertex Pharmaceuticals Corporation Information
Table 80. Vertex Pharmaceuticals Description and Major Businesses
Table 81. Vertex Pharmaceuticals Product Features and Attributes
Table 82. Vertex Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Vertex Pharmaceuticals Recent Developments
Table 84. F. Hoffman La Roche Corporation Information
Table 85. F. Hoffman La Roche Description and Major Businesses
Table 86. F. Hoffman La Roche Product Features and Attributes
Table 87. F. Hoffman La Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. F. Hoffman La Roche Recent Developments
Table 89. Teva Pharmaceuticals Corporation Information
Table 90. Teva Pharmaceuticals Description and Major Businesses
Table 91. Teva Pharmaceuticals Product Features and Attributes
Table 92. Teva Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Teva Pharmaceuticals Recent Developments
Table 94. Cipla Corporation Information
Table 95. Cipla Description and Major Businesses
Table 96. Cipla Product Features and Attributes
Table 97. Cipla Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Cipla Recent Developments
Table 99. Fibrogen Corporation Information
Table 100. Fibrogen Description and Major Businesses
Table 101. Fibrogen Product Features and Attributes
Table 102. Fibrogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Fibrogen Recent Developments
Table 104. Liminal Biosciences Corporation Information
Table 105. Liminal Biosciences Description and Major Businesses
Table 106. Liminal Biosciences Product Features and Attributes
Table 107. Liminal Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Liminal Biosciences Recent Developments
Table 109. PharmAkea Therapeutics Corporation Information
Table 110. PharmAkea Therapeutics Description and Major Businesses
Table 111. PharmAkea Therapeutics Product Features and Attributes
Table 112. PharmAkea Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. PharmAkea Therapeutics Recent Developments
Table 114. IQVIA Corporation Information
Table 115. IQVIA Description and Major Businesses
Table 116. IQVIA Product Features and Attributes
Table 117. IQVIA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. IQVIA Recent Developments
Table 119. Raw Materials Key Suppliers
Table 120. Distributors List
Table 121. Market Trends and Market Evolution
Table 122. Market Drivers and Opportunities
Table 123. Market Challenges, Risks, and Restraints
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Drug Treatment for Respiratory Disease Product Picture
Figure 2. Global Drug Treatment for Respiratory Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Asthma Product Picture
Figure 4. Chronic Obstructive Pulmonary Disease (COPD) Product Picture
Figure 5. Lung Cancer Product Picture
Figure 6. Other Diseases Product Picture
Figure 7. Global Drug Treatment for Respiratory Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Drug Treatment for Respiratory Disease Report Years Considered
Figure 12. Global Drug Treatment for Respiratory Disease Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 14. Global Drug Treatment for Respiratory Disease Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Drug Treatment for Respiratory Disease Revenue Market Share by Region (2020-2031)
Figure 16. Global Drug Treatment for Respiratory Disease Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Asthma Revenue Market Share by Player in 2024
Figure 19. Chronic Obstructive Pulmonary Disease (COPD) Revenue Market Share by Player in 2024
Figure 20. Lung Cancer Revenue Market Share by Player in 2024
Figure 21. Other Diseases Revenue Market Share by Player in 2024
Figure 22. Global Drug Treatment for Respiratory Disease Revenue Market Share by Type (2020-2031)
Figure 23. Global Drug Treatment for Respiratory Disease Revenue Market Share by Application (2020-2031)
Figure 24. North America Drug Treatment for Respiratory Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Drug Treatment for Respiratory Disease Revenue (US$ Million) in 2024
Figure 26. North America Drug Treatment for Respiratory Disease Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Drug Treatment for Respiratory Disease Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Drug Treatment for Respiratory Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Drug Treatment for Respiratory Disease Revenue (US$ Million) in 2024
Figure 33. Europe Drug Treatment for Respiratory Disease Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Drug Treatment for Respiratory Disease Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 36. France Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Drug Treatment for Respiratory Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Drug Treatment for Respiratory Disease Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Drug Treatment for Respiratory Disease Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Drug Treatment for Respiratory Disease Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 48. India Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Drug Treatment for Respiratory Disease Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Drug Treatment for Respiratory Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Drug Treatment for Respiratory Disease Revenue (US$ Million) in 2024
Figure 56. Central and South America Drug Treatment for Respiratory Disease Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Drug Treatment for Respiratory Disease Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Drug Treatment for Respiratory Disease Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Drug Treatment for Respiratory Disease Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Drug Treatment for Respiratory Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Drug Treatment for Respiratory Disease Revenue (US$ Million) in 2024
Figure 62. South America Drug Treatment for Respiratory Disease Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Drug Treatment for Respiratory Disease Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Drug Treatment for Respiratory Disease Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Drug Treatment for Respiratory Disease Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Drug Treatment for Respiratory Disease Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Drug Treatment for Respiratory Disease Revenue (2020-2025) & (US$ Million)
Figure 68. Drug Treatment for Respiratory Disease Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
